| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/IMJ.12138 |
| P698 | PubMed publication ID | 23506471 |
| P50 | author | Mark D Chatfield | Q56545844 |
| Michael J. Boyer | Q56650502 | ||
| P2093 | author name string | J Chen | |
| R Spina | |||
| M M Tin | |||
| S Y Y Chu | |||
| P2860 | cites work | High frequency of radiation pneumonitis in patients with locally advanced non-small cell lung cancer treated with concurrent radiotherapy and gemcitabine after induction with gemcitabine and carboplatin. | Q33384774 |
| Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019. | Q34785001 | ||
| Definitive chemoradiation for the treatment of locally advanced non small-cell lung cancer | Q36935116 | ||
| Combined chemo-radiotherapy for locally advanced non-small cell lung cancer: current status and future development | Q37218411 | ||
| Locally advanced non-small cell lung cancer: the past, present, and future | Q37231669 | ||
| Chemoradiotherapy in locally advanced, unresectable non-small cell lung cancer | Q37492651 | ||
| Outcomes of patients with stage III nonsmall cell lung cancer treated with chemotherapy and radiation with and without surgery | Q37529635 | ||
| The role of chemotherapy and radiation in the treatment of locally advanced non-small cell lung cancer (NSCLC). | Q37617422 | ||
| Prognostic factors in stage III non-small cell lung cancer: a review of conventional, metabolic and new biological variables | Q37929588 | ||
| Prognostic factors in stage III non-small-cell lung cancer | Q40166269 | ||
| Consolidation Docetaxel After Concurrent Chemoradiotherapy in Stage IIIB Non–Small-Cell Lung Cancer: Phase II Southwest Oncology Group Study S9504 | Q44438556 | ||
| The impact of additional prognostic factors on survival and their relationship with the anatomical extent of disease expressed by the 6th Edition of the TNM Classification of Malignant Tumors and the proposals for the 7th Edition | Q45837881 | ||
| Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology | Q46253129 | ||
| Incidence and patterns of isolated brain failure in stage III non-small-cell lung cancer treated with concurrent chemoradiation therapy | Q48656958 | ||
| Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. | Q49058675 | ||
| Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B. | Q50690978 | ||
| P433 | issue | 7 | |
| P921 | main subject | chemoradiotherapy | Q5090613 |
| P304 | page(s) | 790-797 | |
| P577 | publication date | 2013-07-01 | |
| P1433 | published in | Internal Medicine Journal | Q15749165 |
| P1476 | title | Outcomes of chemoradiation for patients with locally advanced non-small-cell lung cancer | |
| P478 | volume | 43 |
| Q35069202 | Hydroferrate fluid, MRN-100, provides protection against chemical-induced gastric and esophageal cancer in Wistar rats | cites work | P2860 |
Search more.